# TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

> **NCT07246304** · EARLY_PHASE1 · RECRUITING · sponsor: **TCRCure Biopharma Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Small Cell Lung Cancer ( SCLC )
- CAR-T Cell Therapy

## Interventions

- **BIOLOGICAL:** TC-D101 CAR-T

## Key facts

- **NCT ID:** NCT07246304
- **Lead sponsor:** TCRCure Biopharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246304, "TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07246304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*